Amide Technologies Announces Complex Peptide Manufacturing Platform, Raises $16.5M to Expedite Frontier Drug Discovery
Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.
- Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.
- New advances in structural biology, recombinant biologics, and AI-driven technologies have improved drug design and delivery methods, overcoming many previous pharmacokinetic behavior drawbacks of peptides .
- “Amide delivers on complex peptide orders that other vendors refuse because peptide sourcing shouldn’t stand in the way of discovery,” said Amide CEO Mark Simon, PhD.
- ITA Software founder and CEO Jeremy Wertheimer is an Amide co-founder and Board Member, alongside MIT Professor of Chemistry Brad Pentelute, PhD.